Petrelintide, with the development name ZP8396, is an amylin analogue designed to be dosed once a week. Zealand Pharma is developing it for the treatment of type 2 diabetes and obesity. Preclinical data suggest it may work better in combination with semaglutide, and in June 2024 the company reported a Phase 1b trial in which participants lost 8.6 percent of body weight over 16 weeks. In March 2025 Roche entered an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialise it, both alone and in a fixed-dose combination with CT-388, for people who are overweight or obese.
Facts
Classification
Approval StatusInvestigational / Clinical Trial 1 Route of Administration Drug ClassLong-acting amylin analog 2 Mechanism of ActionLong-acting amylin analog 2 Connections
Long-Form Articles
Treats
Source Petrelintide (Wikipedia)
Source Petrelintide (Wikipedia)
Sources
1. Petrelintide (Wikipedia)
Lead section
In June 2024 the company announced results for a Phase 1b trial
Treats: Type 2 Diabetes, Lead section [treats]
developed by Zealand Pharma for the treatment of type 2 diabetes and obesity
Treats: Obesity, Lead section [treats]
developed by Zealand Pharma for the treatment of type 2 diabetes and obesity
View the Source2. Roche media release, 5 March 2026, petrelintide Phase II ZUPREME-1
Opening description of petrelintide
Petrelintide is an investigational long-acting amylin analog suitable for once-weekly subcutaneous administration
Phase II ZUPREME-1 results paragraph
once-weekly subcutaneous injections of petrelintide (escalated every fourth week ) resulted in statistically significant
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.